EUVIMEDEUVIMED entdecken
Crossref

Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective

Xiujin Chang, Fangui Qu, Chunxiao Li, Jingtian Zhang, Yanqing Zhang, Yuanyuan Xie, Zhongpeng Fan, Jinlei Bian, Jubo Wang, Zhiyu Li iD, Xi Xu iD

Medicinal Research Reviews · 2024-07 · 44 (4) · 1727-1767

DOI: 10.1002/med.22024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medicinal Research Reviews, online erschienen am 05.02.2024. Verfasst von Xiujin Chang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Chemistry, Pharmaceutical. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 154 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, "Double First-Class" University Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Unprecedented therapeutic targeting of previously undruggable proteins has now been achieved by molecular‐glue‐mediated proximity‐induced degradation. As a small GTPase, G1 to S phase transition 1 (GSPT1) interacts with eRF1, the translation termination factor, to facilitate the process of translation termination. Studied demonstrated that GSPT1 plays a vital role in the acute myeloid leukemia (AML) and MYC‐driven lung cancer. Thus, molecular glue (MG) degraders targeting GSPT1 is a novel and promising approach for treating AML and MYC‐driven cancers. In this Perspective, we briefly summarize the structural and functional aspects of GSPT1, highlighting the latest advances and challenges in MG degraders, as well as some representative patents. The structure‐activity relationships, mechanism of action and pharmacokinetic features of MG degraders are emphasized to provide a comprehensive compendium on the rational design of GSPT1 MG degraders. We hope to provide an updated overview, and design guide for strategies targeting GSPT1 for the treatment of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemistry, PharmaceuticalAnimalsHumansAntineoplastic AgentsProteolysisStructure-Activity Relationship

Stichwörter der Autor:innen

GSPT1molecular gluestructure‐activity relationshipstargeted protein degradationtranslation termination

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China.

ORCID-Profile: Zhiyu Li, Xi Xu

Förderung

  • China Postdoctoral Science Foundation
  • National Natural Science Foundation of China
  • "Double First-Class" University Project
  • Natural Science Foundation of Jiangsu Province

Zitieren

APA

Chang, X., Qu, F., Li, C., Zhang, J., Zhang, Y., Xie, Y., Fan, Z., Bian, J., Wang, J., Li, Z., & Xu, X. (2024). Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective. Medicinal Research Reviews, 44(4), 1727-1767. https://doi.org/10.1002/med.22024

Vancouver

Chang X, Qu F, Li C, Zhang J, Zhang Y, Xie Y, et al. Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective. Medicinal Research Reviews. 2024;44(4):1727-1767. doi:10.1002/med.22024

BibTeX
@article{Chang2024,
  author = {Chang, Xiujin and Qu, Fangui and Li, Chunxiao and Zhang, Jingtian and Zhang, Yanqing and Xie, Yuanyuan and Fan, Zhongpeng and Bian, Jinlei and Wang, Jubo and Li, Zhiyu and Xu, Xi},
  title = {Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective},
  journal = {Medicinal Research Reviews},
  year = {2024},
  volume = {44},
  number = {4},
  pages = {1727--1767},
  doi = {10.1002/med.22024}
}
Kostenlos starten →